EWM
MREO

Endurance Wealth Management’s Mereo BioPharma MREO Stock Holding History

Endurance Wealth Management’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,500
Closed -$4K – 642
2021
Q2 		$4K Hold
1,500
– – ﹤0.01% 568
2021
Q1 		$5K Buy
+1,500
New +$5.3K ﹤0.01% 571

Other funds holding MREO

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Endurance Wealth Management's MREO Position: Q3 2021 in Review

Endurance Wealth Management sold out of Mereo BioPharma (MREO) in Q3 2021, closing a stake of 1,500 shares — an estimated $4K sold.

Endurance Wealth Management first reported a position in MREO in Q1 2021 and held it in 2 quarters. The position peaked at $5K in Q1 2021. 63 funds tracked by Wall St. Rank hold MREO as of Q3 2021.

  • Endurance Wealth Management reported no remaining Mereo BioPharma position as of Q3 2021 after selling out during the quarter.
  • Endurance Wealth Management sold 1,500 Mereo BioPharma shares in Q3 2021, an estimated $4K.
  • Endurance Wealth Management first reported a position in Mereo BioPharma in Q1 2021 and held it in 2 quarters.
  • Endurance Wealth Management's Mereo BioPharma position peaked at $5K in Q1 2021.
  • 63 funds tracked by Wall St. Rank held Mereo BioPharma as of Q3 2021.

Based on Endurance Wealth Management's 13F filing for Q3 2021, filed 28 Oct 2021.